The role of lycopene and its derivatives in the regulation of transcription systems: Implications for cancer prevention

American Journal of Clinical Nutrition

Volumn 96, Issue 5, 2012, Pages

  Sharoni, Yoav ^a   Linnewiel Hermoni, Karin ^a   Zango, Gabriel ^a   Khanin, Marina ^a   Salman, Hagar ^a   Veprik, Anna ^a   Danilenko, Michael ^a   Levy, Joseph ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAROTENOID; LIVER X RECEPTOR; LYCOPENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOID X RECEPTOR; SOMATOMEDIN;

CANCER PREVENTION; ELECTROPHILICITY; HUMAN; NONHUMAN; PHOTOOXIDATION; PHYTONUTRIENT; PROSTATE CANCER; REVIEW; TOMATO; TRANSCRIPTION REGULATION;

ANIMALS; BREAST NEOPLASMS; CAROTENOIDS; CELL LINE, TUMOR; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 84867812447     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.034645     Document Type: Review

References (62)

1. Riboli E, Norat T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am J Clin Nutr 2003;78:559S-69S. (Pubitemid 40012550)
2. Temple NJ, Gladwin KK. Fruit, vegetables, and the prevention of cancer: research challenges. Nutrition 2003;19:467-70. (Pubitemid 36444696)
3. van Poppel G. Carotenoids and cancer: an update with emphasis on human intervention studies. Eur J Cancer 1993;29A:1335-44.
4. Krinsky NI, Johnson EJ. Carotenoid actions and their relation to health and disease. Mol Aspects Med 2005;26:459-516. (Pubitemid 41741836)
5. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 1999;91:317-31. (Pubitemid 29102331)
6. Giovannucci E. Tomato products, lycopene, and prostate cancer: a review of the epidemiological literature. J Nutr 2005;135(suppl):2030S-1S. (Pubitemid 41099768)
7. Amir H, Karas M, Giat J, Danilenko M, Levy R, Yermiahu T, Levy J, Sharoni Y. Lycopene and 1,25-dihydroxyvitamin-D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 1999;33:105-12. (Pubitemid 29196131)
8. Levy J, Bosin E, Feldman B, Giat Y, Miinster A, Danilenko M, Sharoni Y. Lycopene is a more potent inhibitor of human cancer cell proliferation than either α-carotene or β-carotene. Nutr Cancer 1995;24:257-66.
9. Prakash P, Russell RM, Krinsky NI. In vitro inhibition of proliferation of estrogen-dependent and estrogen-independent human breast cancer cells treated with carotenoids or retinoids. J Nutr 2001;131:1574-80. (Pubitemid 32422985)
10. Pastori M, Pfander H, Boscoboinik D, Azzi A. Lycopene in association with alpha-tocopherol inhibits at physiological concentrations proliferation of prostate carcinoma cells. Biochem Biophys Res Commun 1998;250:582-5. (Pubitemid 28484769)
11. Nahum A, Hirsch K, Danilenko M, Watts CK, Prall OW, Levy J, Sharoni Y. Lycopene inhibition of cell cycle progression in breast and endometrial cancer cells is associated with reduction in cyclin D levels and retention of p27(Kip1) in the cyclin E-cdk2 complexes. Oncogene 2001;20:3428-36. (Pubitemid 32588991)
12. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36. (Pubitemid 32166444)
13. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988;48:246-53. (Pubitemid 18045752)
14. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
15. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97. (Pubitemid 29275701)
16. Gaudet MM, Britton JA, Kabat GC, Steck-Scott S, Eng SM, Teitelbaum SL, Terry MB, Neugut AI, Gammon MD. Fruits, vegetables, and micronutrients in relation to breast cancer modified by menopause and hormone receptor status. Cancer Epidemiol Biomarkers Prev 2004;13:1485-94. (Pubitemid 39202316)
17. Cui Y, Shikany JM, Liu S, Shagufta Y, Rohan TE. Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the Women's Health Initiative Observational Study. Am J Clin Nutr 2008;87:1009-18. (Pubitemid 351549247)
18. Hirsch K, Atzmon A, Danilenko M, Levy J, Sharoni Y. Lycopene and other carotenoids inhibit estrogenic activity of 17β-estradiol and genistein in cancer cells. Breast Cancer Res Treat 2007;104:221-30. (Pubitemid 47084226)
19. Veprik A, Khanin M, Linnewiel-Hermoni K, Danilenko M, Levy J, Sharoni Y. Polyphenols, isothiocyanates and carotenoid derivatives enhance estrogenic activity in bone cells but inhibit it in breast cancer cells. Am J Physiol Endocrinol Metab 2011;Aug 30 (Epub ahead of print; DOI:10.1152/ajpendo.00142. 2011).
20. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96. (Pubitemid 351521864)
21. Kaarbø M, Klokk TI, Saatcioglu F. Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 2007;29:1227-38. (Pubitemid 350221791)
22. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.
23. Pourmand G, Salem S, Mehrsai A, Lotfi M, Amirzargar MA, Mazdak H, Roshani A, Kheirollahi A, Kalantar E, Baradaran N, et al. The risk factors of prostate cancer: a multicentric case-control study in Iran. Asian Pac J Cancer Prev 2007;8:422-8.
24. Boileau TW, Liao Z, Kim S, Lemeshow S, Erdman JW Jr, Clinton SK. Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. J Natl Cancer Inst 2003;95:1578-86. (Pubitemid 37455925)
25. Campbell JK, Stroud CK, Nakamura MT, Lila MA, Erdman JW Jr. Serum testosterone is reduced following short-term phytofluene, lycopene, or tomato powder consumption in f344 rats. J Nutr 2006;136:2813-9. (Pubitemid 44771779)
26. Limpens J, Schroder FH, de Ridder CM, Bolder CA, Wildhagen MF, Obermuller-Jevic UC, Kramer K, van Weerden WM. Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J Nutr 2006;136:1287-93.
27. Canene-Adams K, Lindshield BL, Wang S, Jeffery EH, Clinton SK, Erdman JW Jr. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res 2007;67:836-43. (Pubitemid 46192225)
28. Siler U, Barella L, Spitzer V, Schnorr J, Lein M, Goralczyk R, Wertz K. Lycopene and Vitamin E interfere with autocrine/paracrine loops in the Dunning prostate cancer model. FASEB J 2004;18:1019-21. (Pubitemid 39561511)
29. Anderson ML. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and saw palmetto lipid extract in vitro. J Herb Pharmacother 2005;5:17-26. (Pubitemid 41536068)
30. Rittmaster RS. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 2008;22:389-402. (Pubitemid 351611959)
31. Linnewiel K, Ernst H, Caris-Veyrat C, Ben-Dor A, Kampf A, Salman H, Danilenko M, Levy J, Sharoni Y. Structure activity relationship of carotenoid derivatives in activation of the electrophile/antioxidant response element transcription system. Free Radic Biol Med 2009;47:659-67.
32. Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willett WC. Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev 2003;12:84-9. (Pubitemid 36193996)
33. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hannekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6. (Pubitemid 28067285)
34. Levy J, Walfisch S, Walfisch Y, Nahum A, Hirsch K, Danilenko M, Sharoni Y. Tomato carotenoids and the IGF system in cancer. In: Preedy V, Watson R, eds. Tomatoes and tomato products: nutritional, medicinal and therapeutic properties. Enfield, NH: Science Publishers, 2008:397-412.
35. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37. (Pubitemid 36588961)
36. Signorello LB, Kuper H, Lagiou P, Wuu J, Mucci LA, Trichopoulos D, Adami HO. Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 2000;9:173-8. (Pubitemid 30395354)
37. Vrieling A, Voskuil DW, Bueno de Mesquita HB, Kaaks R, van Noord PA, Keinan-Boker L, van Gils CH, Peeters PH. Dietary determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1, -2 and -3 in women in the Netherlands. Cancer Causes Control 2004;15:787-96. (Pubitemid 39335575)
38. Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. Cancer Epidemiol Biomarkers Prev 2002;11:852-61. (Pubitemid 35014888)
39. Gunnell D, Oliver SE, Peters TJ, Donovan JL, Persad R, Maynard M, Gillatt D, Pearce A, Hamdy FC, Neal DE, et al. Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. Br J Cancer 2003;88:1682-6. (Pubitemid 36760409)
40. Mucci LA, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E, Trichopoulos D. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87:814-20. (Pubitemid 34204321)
41. Karas M, Amir H, Fishman D, Danilenko M, Segal S, Nahum A, Koifmann A, Giat Y, Levy J, Sharoni Y. Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 2000;36:101-11. (Pubitemid 30317841)
42. Nahum A, Zeller L, Danilenko M, Prall OW, Watts CK, Sutherland RL, Levy J, Sharoni Y. Lycopene inhibition of IGF-induced cancer cell growth depends on the level of cyclin D1. Eur J Nutr 2006;45:275-82. (Pubitemid 44167661)
43. Talalay P. Chemoprotection against cancer by induction of phase 2 enzymes. Biofactors 2000;12:5-11. (Pubitemid 32107378)
44. Astorg P, Berges R, Suschetet M. Induction of gamma GT- and GST-P positive foci in the liver of rats treated with 2-nitropropane or propane 2-nitronate. Cancer Lett 1994;79:101-6.
45. Dingley KH, Ubick EA, Chiarappa-Zucca ML, Nowell S, Abel S, Ebeler SE, Mitchell AE, Burns SA, Steinberg FM, Clifford AJ. Effect of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhIP and IQ and phase II hepatic rnzymes. Nutr Cancer 2003;46:212-21. (Pubitemid 37500513)
46. Prochaska HJ, Talalay P. Regulatory mechanisms of monofunctional and bifunctional anticarcinogenic enzyme inducers in murine liver. Cancer Res 1988;48:4776-82.
47. Iqbal M, Sharma SD, Okazaki Y, Fujisawa M, Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 2003;92:33-8. (Pubitemid 36238075)
48. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA 2002;99:11908-13. (Pubitemid 34994497)
49. Kwak MK, Egner PA, Dolan PM, Ramos-Gomez M, Groopman JD, Itoh K, Yamamoto M, Kensler TW. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutat Res 2001;480-481:305-15. (Pubitemid 32744837)
50. Kong AN, Owuor E, Yu R, Hebbar V, Chen C, Hu R, Mandlekar S. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001;33:255-71. (Pubitemid 33136265)
51. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam J, De Galarreta CM, Cuadrado A. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004;279:8919-29. (Pubitemid 38295953)
52. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R, Alam J, Motterlini R. Curcumin activates the heme oxygenase-1 gene via regulation of Nrf2 and the antioxidant responsive element. Biochem J 2003;371:887-95. (Pubitemid 36578887)
53. Talalay P, Fahey JW. Phytochemicals from cruciferous plants protect against cancer by modulating carcinogen metabolism. J Nutr 2001;131:3027S-33S. (Pubitemid 33070774)
54. Gradelet S, Astorg P, Leclerc J, Chevalier J, Vernevaut MF, Siess MH. Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica 1996;26:49-63. (Pubitemid 26108102)
55. Breinholt V, Lauridsen ST, Daneshvar B, Jakobsen J. Dose-response effects of lycopene on selected drug-metabolizing and antioxidant enzymes in the rat. Cancer Lett 2000;154:201-10. (Pubitemid 30259228)
56. Ben-Dor A, Steiner M, Gheber L, Danilenko M, Dubi N, Linnewiel K, Zick A, Sharoni Y, Levy J. Carotenoids activate the antioxidant response element transcription system. Mol Cancer Ther 2005;4:177-86. (Pubitemid 40268075)
57. Huang CS, Fan YE, Lin CY, Hu ML. Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1. J Nutr Biochem 2007;18:449-56.
58. Bonvissuto G, Minutoli L, Morgia G, Bitto A, Polito F, Irrera N, Marini H, Squadrito F, Altavilla D. Effect of Serenoa repens, lycopene, and selenium on proinflammatory phenotype activation: an in vitro and in vivo comparison study. Urology 2011;77:248.e9-e16.
59. Ziouzenkova O, Orashanu G, Sukhova G, Lau E, Berger JP, Tang G, Krinsky NI, Dolnikowski GG, Plutzky J. Asymmetric cleavage of β-carotene yields a transcriptional repressor of RXR and PPAR responses. Mol Endocrinol 2007;21:77-88.
60. Eroglu A, Hruszkewycz DP, Curley RW Jr, Harrison EH. The eccentric cleavage product of beta-carotene, beta-apo-13-carotenone, functions as an antagonist of RXRalpha. Arch Biochem Biophys 2010;504:11-6.
61. Harrison EH, dela Sena C, Eroglu A, Fleshman MK. The formation, occurrence, and function of β-apocarotenoids: β-carotene metabolites that may modulate nuclear receptor signaling. Am J Clin Nutr 2012;96(suppl):1189S-92S.
62. Yang CM, Lu IH, Chen HY, Hu ML. Lycopene inhibits the proliferation of androgen-dependent human prostate tumor cells through activation of PPARgamma-LXRalpha-ABCA1 pathway. J Nutr Biochem 2012;23:8-17.